<?xml version='1.0' encoding='utf-8'?>
<document id="28067989"><sentence text="Tacrolimus interaction with nafcillin resulting in significant decreases in tacrolimus concentrations: A case report."><entity charOffset="28-37" id="DDI-PubMed.28067989.s1.e0" text="nafcillin" /></sentence><sentence text="Tacrolimus (TAC) is subject to many drug interactions as a result of its metabolism primarily via CYP450 isoenzyme 3A4" /><sentence text=" Numerous case reports of TAC and CYP3A4 inducers and inhibitors have been described including antimicrobials, calcium channel antagonists, and antiepileptic drugs"><entity charOffset="111-118" id="DDI-PubMed.28067989.s3.e0" text="calcium" /></sentence><sentence text=" We present the case of a 13-year-old patient with cystic fibrosis and a history of liver transplantation, where subtherapeutic TAC concentrations were suspected to be a result of concomitant TAC and nafcillin (NAF) therapy"><entity charOffset="200-209" id="DDI-PubMed.28067989.s4.e0" text="nafcillin" /><entity charOffset="211-214" id="DDI-PubMed.28067989.s4.e1" text="NAF" /><pair ddi="false" e1="DDI-PubMed.28067989.s4.e0" e2="DDI-PubMed.28067989.s4.e0" /><pair ddi="false" e1="DDI-PubMed.28067989.s4.e0" e2="DDI-PubMed.28067989.s4.e1" /></sentence><sentence text=" The observed drug interaction occurred on two separate hospital admissions, during both of which the patient exhibited therapeutic TAC concentrations prior to exposure to NAF, a CYP3A4 inducer"><entity charOffset="172-174" id="DDI-PubMed.28067989.s5.e0" text="NAF" /></sentence><sentence text=" Upon discontinuation of NAF, TAC concentrations recovered in both instances"><entity charOffset="25-28" id="DDI-PubMed.28067989.s6.e0" text="NAF" /></sentence><sentence text=" This case represents a drug-drug interaction between TAC and NAF that has not previously been reported to our knowledge"><entity charOffset="62-64" id="DDI-PubMed.28067989.s7.e0" text="NAF" /></sentence><sentence text=" Despite the lack of existing reports of interaction between these two agents, this case highlights the importance of therapeutic drug monitoring and assessing for any potential drug-drug or drug-food interactions in patients receiving TAC therapy" /><sentence text="" /></document>